Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Axsome Therapeutics Inc AXSM

Healthcare Biotechnology
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:AXSM)

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue

GlobeNewswire 14 hours ago

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation

GlobeNewswire December 30, 2024

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

GlobeNewswire November 26, 2024

Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 12, 2024

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

GlobeNewswire November 8, 2024

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

GlobeNewswire October 29, 2024

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

GlobeNewswire October 15, 2024

Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024

GlobeNewswire September 24, 2024

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

GlobeNewswire September 4, 2024
View More News ››

Opinion & Analysis (NDAQ:AXSM)

'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug

Streetwise Reports July 2, 2020

Biopharma to Accelerate Alzheimer Trial Completion

Streetwise Reports March 26, 2020

Two Stock-Moving Catalysts Expected in March for Biopharma

Streetwise Reports February 26, 2020

Biopharma's Phase 3 Trial Results in Migraine 'Robust,' 'Impressive'

Streetwise Reports January 6, 2020

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

Streetwise Reports December 17, 2019

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

Streetwise Reports December 4, 2019
View More Opinion ››

Bullboard Posts (NDAQ:AXSM)

Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript

BREAKING NEWS: $AXSM Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript2024-11-12 15:15:17 ET Image source: The Motley Fool...
whytestocks - November 12, 2024

Axsome Therapeutics Reports Third Quarter 2024 Financial Res

BREAKING NEWS: $AXSM Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateTotal 3Q 2024 net...
whytestocks - November 12, 2024

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmis

NEWS: $AXSM Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of MigraineNEW YORK...
whytestocks - September 4, 2024

Buy Recommendation Issued On AXSM By Guggenheim

News; $AXSM Buy Recommendation Issued On AXSM By Guggenheim2024-06-11 16:30:03 ET Guggenheim analyst issues BUY recommendation for AXSM...
whytestocks - June 11, 2024

Neurology-Focused Axsome Therapeutics Reports Deeper Than Ex

NEWS: $AXSM Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones...
whytestocks - February 20, 2024

Axsome Therapeutics Reports Fourth Quarter and Full Year 202

BREAKING NEWS: $AXSM Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateTotal...
whytestocks - February 20, 2024
View more Bullboard ››

Nextleaf Solutions Ltd

Nextleaf Solutions Ltd

Nextleaf is a federally regulated manufacturer and distributor of cannabis vapes and oils under its prohibition-era brand ...
View More »